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Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with devastating effects. Currently, therapeutic
options are limited to symptomatic treatment. For more than a decade, research focused on immunotherapy for the causal
treatment of AD. However, clinical trials with active immunization using Ab encountered severe complications, for example
meningoencephalitis. Consequently, attention focused on passive immunization using antibodies. As an alternative to large
immunoglobulins (IgGs), Ab binding single-chain variable fragments (scFvs) were used for diagnostic and therapeutic
research approaches. scFvs can be expressed in E. coli and may provide improved pharmacokinetic properties like increased
blood-brain barrier permeability or reduced side-effects in vivo. In this study, we constructed an scFv from an Ab binding
IgG, designated IC16, which binds the N-terminal region of Ab (Ab(1-8)). scFv-IC16 was expressed in E. coli, purified and
characterized with respect to its interaction with different Ab species and its influence on Ab fibril formation. We were able
to show that scFv-IC16 strongly influenced the aggregation behavior of Ab and could be applied as an Ab detection probe
for plaque staining in the brains of transgenic AD model mice. The results indicate potential for therapy and diagnosis of
AD.
Citation: Dornieden S, Mu¨ller-Schiffmann A, Sticht H, Jiang N, Cinar Y, et al. (2013) Characterization of a Single-Chain Variable Fragment Recognizing a Linear
Epitope of Ab: A Biotechnical Tool for Studies on Alzheimer’s Disease? PLoS ONE 8(3): e59820. doi:10.1371/journal.pone.0059820
Editor: Riqiang Yan, Cleveland Clnic Foundation, United States of America
Received November 26, 2012; Accepted February 19, 2013; Published March 26, 2013
Copyright:  2013 Dornieden et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: SD was supported by a fellowship of the International Helmholtz Research School on Biophysics and Soft Matter (BioSoft) granted to DW. CK was
supported by EU-FP7 grant PRIORITY. SAF, CK and DW were supported by a grant from the KNDD/rpAD (BMBF 01ED1201B). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: a.funke@fz-juelich.de
Introduction
Alzheimer’s disease (AD) is a devastating, progressive, neuro-
degenerative disorder, which affects more than 35 million people
world-wide [1]. Currently, AD treatment is restricted to palliative
care due to the lack of disease arresting or modifying therapies [2].
Several lines of evidence have indicated that the amyloid-b-
peptide (Ab) plays a pivotal role in the pathology of AD. Ab is
produced throughout life as a 38 to 43 residue peptide derived
from the amyloid precursor protein (APP) after cleavage by two
distinct proteases, called b- and c-secretase [3,4,5]. The function
of Ab needs to be clarified, but recent studies suggest
neuroprotective effects of monomeric Ab (for review, see ref.
[6]). Senile plaques in the brain of the patient, one of the typical
histopathological hallmarks of AD, consist mainly of Ab(1-42).
They are thought to play a crucial role in the pathology of AD,
and according to the original amyloid cascade hypothesis, Ab
deposited in plaques has been thought to be responsible for
neuronal dysfunction [7,8]. However, Ab can adopt a variety of
neurotoxic conformers (for review, see ref. [9]), and more recent
studies indicate that diffusible Ab oligomers are the major toxic
species during disease development and progression [10,11,12,13].
Consequently, agents that interfere with Ab oligomerization or
increase Ab clearance from the brain are expected to be valuable
for application in therapy or prevention of AD. Passive
immunotherapeutic approaches, i.e. direct administration of Ab
antibodies peripherally, were shown to be effective in transgenic
mouse models of AD [14,15,16,17]. A variety of humanized
monoclonal antibodies are currently investigated in clinical trials
(for review, see ref. [18]). However, two phase III clinical trials
with antibodies were discontinued as they failed to improve
cognitive functions in the treated patients [19].
Additionally, Ab binding ligands can be valuable for the
investigation of the plaque load by in vivo imaging methods.
Currently, only a few amyloid PET ligands have been applied in
clinical studies (for review, see ref. [20,21]). Numerous efforts are
devoted to develop new, target-specific imaging agents for the
detection of amyloid plaques in vivo. To be suitable, such
substances should exhibit highly specific binding to Ab aggregates,
very selective labeling and efficient brain penetration.
Targeting Ab using scFvs have been shown to be a suitable
alternative to IgGs [22]. ScFvs are genetically engineered
constructs composed of the variable regions of the heavy-(VH)
and light chain (VL) domains of a respective antibody, connected
by a flexible linker to prevent dissociation. They usually retain the
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specific and monovalent antigenic binding affinity of the parent
IgG, but can exhibit improved pharmacokinetic properties like
increased blood-brain barrier permeability [23]. Because of their
small size, they can be recombinantly expressed in living systems,
offering advantages for protein expression in microbial hosts and
purification with high yield [24], as well as for gene therapeutic
approaches that could avoid repeated infusions of expensive
antibodies like performed in passive immunotherapy. Due to the
lack of the constant domain (FC) in scFvs, FC induced cellular
responses, microhemorrhages and inflammatory processes are
prevented [25]. These advantages prompted the generation of
several Ab-binding scFvs that interact with Ab, influence Ab
aggregation and partially reduce Ab cytotoxicity in cell culture
[26,27,28]. Recently, adeno-associated virus (AAV)-mediated
intramuscular expression of a gene encoding for a scFv against
the N-terminal part of Ab, isolated from a human scFv library
[29], was demonstrated to be effective in removing Ab from the
brain of AD transgenic mice without inducing hemorrhages or
inflammation. Additionally, the cognitive performance of treated
mice was improved in comparison with control mice [30].
Furthermore, another scFv binding to the C-terminus of Ab,
constructed using an antibody that was generated by immunizing
mice with Ab(30-42), has been shown to reduce congiophilic
angiopathy as well as plaque burden in APP transgenic mice after
direct chronic intranasal treatment [31].
We have constructed a scFv derived from an Ab binding
monoclonal antibody IC16, designated scFv-IC16. ScFv-IC16 was
expressed in E. coli, purified and characterized with respect to its
interaction with different Ab species and its influence on Ab
fibrilization. Additionally, scFv-IC16 was used to stain and
characterize plaques in brain slices of transgenic AD model mice
by immunohistochemistry. scFv-IC16 was conclusively found to be
a remarkable antibody fragment for the investigation of molecular
pathological mechanisms, therapy or diagnosis of AD.
Materials and Methods
Molecular Modeling
The structure of IC16 in complex with Ab(1-8) was generated
with Modeller [32] using the crystal structure of the Ab(1-8)-bound
antibody PFA1 as template (pdb code 2IPU; [33]). The model was
completed using Sybyl7.3 (Tripos Inc., St. Louis, MO, USA) by
addition of Ab-residue D1, which was not resolved in the PFA-Ab
crystal structure, followed by 100 steps of conjugate gradient
energy minimization. The quality of the resulting model was
checked using WhatCheck [34] and intermolecular contacts were
analyzed with LigPlot [35].
Materials
All chemicals were supplied by AppliChem GmbH (Darmstadt,
Germany), Merck (Darmstadt, Germany), Sigma Aldrich (St.
Louis, MO, USA), and Roth (Karlsruhe, Germany) in research
grade. All peptides were purchased as reversed phase high
performance liquid chromatography purified products (purity .
95%). Synthetic human Ab(1-42) was purchased from Bachem
(Bubendorf, Switzerland). N-terminally biotinylated Ab(1-42) was
purchased from Anaspec (Fremont, CA, USA). Ab peptides Ab(1-
8)-GSGSC, Ab(2-8)-GSGSC, Ab(3-8)-GSGSC, and Ab(8-15)-
GSGSC were purchased from JPT (Berlin, Germany).
Construction of an IC16 Single-chain Variable Fragment
(scFv-IC16) Expression Plasmid
The monoclonal IgG2a antibody IC16 recognizes Ab(1-8) and
has been described earlier [36]. Briefly, an IC16 hybridoma was
generated by standard fusion procedure of myeloma cells with
splenocytes from a PrP knockout mouse [37] immunized with
KLH Ab(1-16). A scFv was constructed with mRNA purified from
IC16 hybridoma used for PCR amplification with primers specific
for variable regions of the heavy (VH) and light chain (VL): VH
forward: 59- AAAACCATGGCGCAGGTTACTCTGAAA-
GAGTC-39; VH reverse: 59 TTTTGCCGGCCAG TGGATA-
GACCGATGGGGCTGTTGTTTTGGT-39; VL forward: 59
AAAAGGATCCGATGTTTTGATGACCCAAACT-39;VL re-
verse: 5- AAAAGCGGCCGCGGATACAGTTGGTGCAG-
CATC-39. PCR products were digested with NgoMIV (VH) or
BamHI (VL) and ligated to a oligonucleotide coding for a (Gly4Ser)3
linker domain [38]. The resulting 800 bp product was eluted from
agarose gel and amplified with VH forward and VL reverse primer.
The amplificate was digested with NcoI and EagI and ligated into
pET22b (Merck, Darmstadt, Germany), allowing periplasmic
expression of the IC16-scFv fused to a His6- and Myc-tag. The
complete amino acid sequence of scFv-IC16 is as follows:
MKYLLPTAAAGLLLLAAQPAMAMAQVTLKESGP-
GILQPSQTLSLTCSFSGFSLSTSGMGV.
SWIRQPSGKGLEWLAHIFWDDD-
KNYNPSLKSRLTVSKDTSRNQVFLKITSVDTSDTATYY.
CARSPHLRGYDVDFDYWGQGTTLTVSSAKTTAPSVY-
PLAGGGGSGGGGSGGGGSDVLMTQ.
TPLSLPVSLGDQASISCRSSQSLVHSNGNTYLH-
WYLQKPGQSPKVLIYKVSNRFSGVPDR.
FSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPLTF-
GAGTKLELKRADAAPTVSAAEEQ.
KLISEEDLEEEEEEGTLEHHHHHH.
Generation of Ab(1-16)-GB1-NHS-Sepharose for
Purification of scFv-IC16
For expression of Ab(1-16)-GB1 (Ab-GB1), human Ab(1-16)
was ligated into the Nde1 site of pET22b-GB1 [39]. Ab-GB1 was
expressed at 37uC in BL21(DE3) Rosetta (Merck, Darmstadt,
Germany) grown to mid-logarithmic phase in 2YT-medium.
Expression was induced by the addition of IPTG to a final
concentration of 1 mM, and cells were then grown for a further
4 h. After harvesting cells by centrifugation, they were lysed in
50 mM Tris-HCl (pH 8.0), 5 mM EDTA, 1% Triton X-100,
2 mM phenylmethanesulfonyl fluoride (PMSF), 20 mM MgCl2,
200 U DNase1 and 0,25 mg/ml lysozyme. The cleared lysate was
first dialyzed to 20 mM Tris-HCl (pH 8.0) and 1 mM EDTA and
the first purification step was then performed via Q-Sepharose
(GE Healthcare, Little Chalfont, UK). The column was washed
with dialysis buffer and bound Ab-GB1 was eluted with 20 mM
Tris-HCl (pH 8.0), 1 mM EDTA and 75 mM NaCl. In a final
purification step, Ab-GB1 was separated from minor impurities
using IgG-Sepharose (GE Healthcare). After washing with 20 mM
Tris-HCl (pH 8.0), 150 mM NaCl and 1 mM EDTA, Ab-GB1
was eluted with 50 mM glycine pH 2.5 and immediately
neutralized by adding Tris-HCl (pH 8.0) to a final concentration
on 100 mM. After dialysis against PBS the protein was coupled to
NHS-Sepharose (GE Healthcare, Little Chalfont, UK) according
to the manufacturer’s recommendations.
Expression and Purification of scFv-IC16
Escherichia coli strain BL21(DE3)pRARE2 was used as an
expression host. Bacteria were grown to high density
(OD600$1.6) at 37uC, and cooled on ice for 1 h before induction
with IPTG at a final concentration of 0.1 mM. Cells were further
incubated for 24 h at 18uC, and subsequently harvested by
centrifuging for 30 min at room temperature at 50006g. Cells
were lysed in 20 mM Tris-HCl pH 8.0, 0.4 mM EDTA, 5 mM
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imidazole, 500 mM NaCl, 20 mM MgCl2, 10 mM CaCl2,
Protease Inhibitor Cocktail Tablet Complete EDTA free (Roche,
Grenzach-Wyhlen, Germany), 1 mg/ml lysozyme and 500 U
DNase. The lysate was cleared by centrifugation at 20 0006g, and
the soluble protein in the supernatant was purified via Ni-NTA
chromatography (Ni-NTA Agarose, AppliChem GmbH, Darm-
stadt, Germany). After loading the sample onto the Ni-NTA
Agarose, the column (3 ml) was washed with 10 column volumes
(CV) 20 mM Tris-HCl pH 8.0, 5 mM imidazole, 500 mM NaCl
and 1% TX-100, followed by a second wash with 10 CV 20 mM
Tris-HCl pH 8.0, 5 mM imidazole, 500 mM NaCl. Bound scFv-
IC16 was eluted by four CV elution buffer (20 mM Tris-HCl
pH 8.0, 300 mM imidazole, and 300 mM NaCl). A second
purification step using affinity chromatography was performed,
because the purity of the eluted protein was lower than 50%. The
previously generated Ab1-16-GB1 NHS sepharose was used for
a subsequent purification step. After loading scFv-IC16 (in elution
buffer), the column was washed with 10 CV TBS (137 mM NaCl,
2.7 mM KCl, 2.5 mM Tris-HCl, pH 7.4). The protein was eluted
with 50 mM glycine, pH 2.5 and immediately neutralized with
a final concentration of 100 mM Tris-HCl, pH 8.0. ScFv-IC16
was dialyzed against PBS (137 mM NaCl, 2.7 mM KCl, 1.8 mM
KH2PO4, 10 mM Na2HPO4, pH 7.4) and stored at 220uC until
further usage.
Binding Constant Determination Using Surface Plasmon
Resonance (SPR)
Binding kinetics were determined by SPR using a BiacoreTM X
(GE Healthcare, UK). Synthetic Ab peptides were dissolved in
10 mM NaAc, pH 4.0. The CM5 sensor chip surface (GE
Healthcare, UK) was activated using N-ethyl-N9-3 (diethylamino-
propyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS)
chemistry followed by 2-(2-pyridinyldithio)ethaneamine hydro-
chloride (PDEA), in order to introduce a reactive thiol group. Ab
was coupled via the C-terminal cysteine to the chip at a flow rate
of 5 ml/min, and the remaining active groups were blocked by
injecting cysteine. The immobilization procedure was performed
according to manufacturer’s recommendation. All kinetic analyses
were performed at a flow rate of 20 ml/min in PBS. Varying
concentrations of scFv-IC16 (10 to 5000 nM) and IC16 (10 to
1000 nM) were injected. Association was observed for 180 s
whereas the dissociation was observed for 120 to 360 s. When
required, the surface was regenerated by injecting 20 ml 50 mM
glycine, pH 11.0. The data evaluation was performed using
Biaevaluation Software 4.1.1. ScFv-IC16 data were fitted accord-
ing to the Langmuir 1:1 binding model, whereas IC16 data were
fitted according to the bivalent binding model. Standard errors of
equilibrium dissociation constants (KD) were calculated using
standard errors of the corresponding association and dissociation
rate constants [40].
Thioflavin T (ThT) Assays
7.5 mM Ab(1-42) (stock solution of 190 mM in DMSO, freshly
prepared before usage) were incubated with 10 mMThT in PBS in
absence or presence of different concentrations of scFv-IC16 (1.5,
3.75 and 7.5 mM) at room temperature for 24 h. In addition, scFv-
IC16 (7.5 mM) without Ab(1-42) was tested under the same
conditions as the negative control. For all samples a reference
value, generated with PBS and ThT only, was subtracted. Each
sample had a volume of 50 ml and was incubated and measured in
a 384 well plate (Greiner 384 Well polypropylene Greiner Bio-
One GmbH, Frickenhausen, Germany). The plate was covered by
an adhesive film preventing evaporation of the sample buffer.
Fluorescence recordings were performed every 30 min for 22 h
(excitation wavelength 440 nm, emission wavelength 490 nm,
Polarstar Optima, BMG, Ortenberg, Germany). The experiments
were performed five-fold, and the average of the obtained values
as well as the standard deviation was calculated.
Seedless-preparation of Ab1-42
1 mg of Ab(1-42) or N-terminally/C-terminally biotinylated
Ab(1-42) was dissolved in 1 ml 1,1,1,3,3,3-hexafluorosiopropanol
(HFIP) and incubated overnight at room temperature. Afterwards,
Ab(1-42) was mixed in the favored ratio with N-terminally/C-
terminally biotinylated Ab(1-42) and aliquoted. HFIP was
evaporated using a SpeedVac (Concentrator 5301, Eppendorf,
Germany) at room temperature for 30 min. To evaporate
remaining HFIP, the sample was incubated overnight at room
temperature with an open lid.
Preparation of Ab(1-42) Monomers, Oligomers and Fibrils
The preparation of Ab(1-42) monomers and oligomers was
carried out by size exclusion chromatography (SEC) as already
described by Johansson et al [41] with minor modifications.
250 mg of Ab peptide was dissolved in 130 ml SEC buffer (50 mM
NaPi, pH 7.4; 150 mM NaCl; 0.6% Tween-20) and briefly
centrifuged (1 min, 16 1006g, room temperature) to remove
insoluble fibrillar material. 100 ml of the supernatant was applied
on a Superdex75 10/300 column (GE Healthcare, UK) connected
to an A¨kta purifier system (GE Healthcare, UK). The sample was
eluted at a flow rate of 0.6 ml per min at room temperature and
detected at wavelengths of 214, 250 and 278 nm. Fractions of
200 ml were collected. For the preparation of Ab fibrils, 125 mg of
Ab(1-42) peptide was dissolved in 200 ml PBS and incubated for
24 h (3006g, 37uC). Samples were centrifuged (16 1006g,
20 min, room temperature) and the supernatant containing
soluble Ab species was discarded. Insoluble fibrils were resus-
pended in 200 ml SEC buffer. The concentration of the Ab
preparations was determined using the Micro BCA Protein Assay
Kit (Thermo Scientific, Waltham, MA, USA). Before performing
the standard protocol recommended by the manufacturer, 80 ml
6 M urea was mixed with 80 ml monomer- and oligomer
preparation, respectively. As the concentration of the fibril
preparation was usually high, 80 ml 6 M Urea was mixed with
40 ml SEC buffer and 40 ml fibril fraction. The samples were
incubated at 60uC for 30 min. Afterwards they were mixed with
BCA reagent at a ratio of one to one and again incubated at 60uC
for 20 to 30 min. Bovine serum albumin (BSA) at concentrations
of 10, 20 and 40 mg per ml was used as a standard. The samples
were measured at a wavelength of 570 nm with a Polarstar
Optima plate reader (BMG, Ortenberg, Germany).
Enzyme-linked Immunosorbent Assay (ELISA) Analysis of
scFv-IC16 Binding to Ab-monomers, -oligomers and -
fibrils
An ELISA was applied to characterize the binding affinity of
scFv-IC16 to different Ab conformers. After concentration de-
termination of the Ab(1-42) monomer, oligomer and fibril
preparations, each conformer was diluted in immobilization buffer
(0.1 M NaHCO3, pH 9.3) to a concentration of 5 mg/ml, and
coated on Nunc immobilizer streptavidin F96 clear plates
(250 ng/well) (Nunc, Thermo Scientific, Waltham, MA, USA).
Alternatively, Ab monomers were prepared seedless in the same
concentration by dissolving 50 mg N-terminally biotinylated Ab(1-
42) in 1 ml immobilization buffer and diluting it further to 5 mg/
ml. N- or C-terminally biotinylated Ab(1-10) peptides were
dissolved in immobilization buffer to a final concentration of
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1.2 mg/ml (60 ng/well). 50 ml of these Ab solutions were in-
cubated in the well for 1 h. Each well was washed with 100 ml
immobilization buffer and the plate was stored at 4uC overnight in
100 ml immobilization buffer per well. Unspecific binding sites
were blocked with 50 ml blocking buffer (PBS, 1% BSA) at room
temperature for 1 h. After removal of the blocking buffer,
a solution of either scFv-IC16 (12 and 23 nM in PBS-T (0.1%
Tween-20) and 0.1% BSA respectively), IC16 (0.67 nM PBS-T
and 0.1% BSA) or mAB-6E10 (0.67 nM PBS-T and 0.1% BSA)
was added to each conformer and incubated for 1 h. Sub-
sequently, each well was washed with PBS-T (three times, 100 ml)
and incubated with Penta-His antibody (Qiagen, Hilden, Ger-
many, dilution 1:500, in 2 ml TBS-T) for 1 h at room
temperature. This was followed by another three washing steps
with PBS-T and detection of the antibodies with HRP-conjugated
anti-mouse IgG (Thermo Scientific, Waltham, MA, USA, dilution
1:10000, in 2 ml TBS-T). 3,3,5,5-tetramethylbenzidine (Sigma
Aldrich, St. Louis, MO, USA) was used as the substrate for the
HRP. The reaction was terminated by adding sulfuric acid to
a final concentration of 1 M. The absorbance was recorded at
450 nm on Polarstar Optima plate reader (BMG, Ortenberg,
Germany).
Immunoprecipitation of Cell Culture Derived Ab
Purified scFv-IC16 was dialyzed against PBS and coupled to
NHS-Sepharose (GE, Buckinghamshire, UK) according to the
manufacturers recommendations. Conditioned medium (CM) was
prepared from confluent wild type CHO cells or 7PA2 cells
cultured in DMEM (Life Technologies, UK) in presence or
absence of FCS. Ab was immune-precipitated from cleared CM
with scFv-IC16-NHS-Sepharose overnight at 4uC. After washing
with PBS, captured proteins were separated by 10–20% tricine
peptide PAGE (Biorad, Hercules, CA) and transferred onto
a 0.2 mm nitrocellulose membrane at 400 mA for 2 h. The filter
was boiled for 5 min in PBS [42] and blocked overnight at 4uC
with 5% fat-free milk in PBS containing 0.05% Tween 20 (PBS-
T). After washing in PBS-T, the membrane was probed with 1:200
diluted monoclonal 4G8 (Signet, Dedhem, MA). Bound antibody
was detected with horseradish peroxidase conjugated goat anti-
mouse Ig (at 1:25000) (Thermo Scientific, Bonn, Germany).
Subsequently, the Amersham ECL Western Blotting Detection
Reagent (GE, Buckinghamshire, UK) was applied for visualiza-
tion.
Ex vivo Staining of Plaques in Mouse Brain Slices
Deep frozen horizontal brain cryosections (20 mm thickness)
from 9 or 12 months old Tg2576 mice and the respective wildtype
control were dried in ambient air for 15 min, and then fixed in ice-
cold 4% (w/v) paraformaldehyde for 20 min. Incubation with
70% formic acid for 5 min was performed to enhance immuno-
reactivity. Sections were permeabilized with 1% Triton X-100 in
TBS for 10 min, followed by blocking with Mouse on mouse
(M.O.M.) Basic Kit (Vector Laboratories) in TBS-Triton (1%, v/v)
for 30 min. Primary antibodies were diluted in 1% BSA/TBS-
Triton (working concentration of ScFv: 400 nM, 6E10:33 nM, 1-
11-3 (Covance, USA) in 1:200 dilution) and probed on the sections
for 1 h, incubating at room temperature. For double staining of
scFv-IC16 and 1-11-3, the respective antibodies were mixed
directly in 1% BSA/TBS-Triton buffer. Subsequently, the slices
were incubated overnight at 8uC in a humid chamber. For His-
tagged scFv, sections were incubated with anti Penta-His Mouse
antibody (Qiagen) 1:10 diluted in 1% BSA/TBST for 2 h at room
temperature. A secondary antibody (Goat anti Mouse Alexa 488,
Invitrogen), diluted 1:300 in 1% BSA/TBST, was incubated for 2
hours at room temperature. For double staining, two secondary
antibodies (goat anti mouse-Alexa488 and goat anti rabbit-Alexa-
568 were mixed directly (working concentration of goat anti
rabbit-Alexa568:1.300). After 1 min of incubation with 0.5 mg/ml
DAPI, the sections were coverslip-mounted with Aqua Poly/Mont
(Polysciences Inc, Worrington, PA, USA). Sections were examined
under a fluorescence microscope (Leica LMD6000 (Leica, Solms,
Germany). Excitation Range: UV; blue; green. Excitation Filter:
Bp 420/30; Bp 495/15; Bp 570/20) with camera (Leica DFC 310
FX). Images were processed with LAS software (Leica Application
Suite, V.4.0.0) and ImageJ (1.45 s).
Results
Expression of scFv-IC16 in E. coli and Purification via Ni-
NTA and Ab-affinity Chromatography
To characterize scFv-IC16, the protein was produced in E. coli
and purified via Ni-NTA and Ab-affinity chromatography.
Expression was performed using the BL21DE3 pRARE2 strain.
ScFv expression often results in formation of inclusion bodies
[43,44]. Therefore, we have developed a protocol for slow
expression, leading to an increase of correctly folded and soluble
protein. Cells were shocked on ice for 1 h after reaching the
stationary phase (OD600$1.6) in order to slow down the
metabolism. Protein expression was induced with a final IPTG
concentration of 0.1 mM. Under these conditions more than 10%
of the expressed protein was soluble. Attempts to purify the
remaining unsoluble protein after denaturation were successful
and yielded pure protein after Ni-NTA affinity chromatography.
However, refolding attempts remained unsuccessful. Purification
of natively folded protein was performed using Ni-NTA affinity
chromatography, followed by Ab affinity chromatography using
Ab(1-16)-GB1 NHS Sepharose. IC16 was originally raised against
Ab(1-16). Therefore, the fusion protein contains the binding
epitope of scFv-IC16. In addition, this step ensured that only
active and correctly folded scFv was purified and thus used for
further studies. The complete procedure resulted in 0.460.1 mg of
pure protein as judged by SDS-PAGE (Fig. 1) and UV/Vis
spectrometry, derived from 1 L cell culture.
Characterization of the Binding Site of scFv-IC16 at Ab(1-
16) – Homology Modeling and Surface Plasmon
Resonance Measurements
The amino acid sequence of the constructed scFv-IC16 was
compared to antibody fragments that were already described in
the literature. The IgG2a monoclonal anti-Ab protofibril anti-
bodies PFA1 and PFA2 were derived from mice challenged with
a stabilized protofibril form of Ab(1-40). The derived Fab
fragments exhibit binding to Ab monomers in the nM range,
but the binding to aggregated Ab forms is significantly impaired in
comparison to the full IgG molecules. Structural characterization
of the Fabs in complex with the Ab(1-8) peptide as well as binding
studies revealed a significant influence of N-terminal Ab trunca-
tions on binding [33]. Our alignments exhibited sequence
identities of 82% and 94% for the VH and VL regions of scFv-
IC16 and the Fab fragment PFA1, respectively (Fig. 2, [33]). In
addition, the complementary determining regions (CDR), which
are hypervariable and mainly determine the binding properties of
an antibody [45], showed high similarity of scFv-IC16 to PFA1
(see also Tables 1 and 2). Therefore, we assume that the binding of
scFv-IC16 is similar to Ab as shown for PFA1 and Ab(1-8) by X-
ray crystallography. To understand the binding of scFv-IC16 to
Ab and the differences to the binding of PFA1 to Ab in more
detail, the structure of scFv-IC16 in complex with Ab(1-8) was
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modeled using the crystal structure of the Ab(1-8)-PFA1 complex
[33] as a template. As expected from the high degree of sequence
similarity, both antibodies form similar contacts with Ab(1-8)
(Fig. 3). Differences are only detected for sequence positions 100
and 108 of the heavy chain, as well as 98 of the light chain. Of
these three sites, only residue 108 forms significant interactions
with Ab(1-8). In PFA1, D108(H) forms a salt-bridge with H6 of
Ab, while V108(H) of IC16 forms nonpolar interactions with H6
(Fig. 3).
Our next aim was to confirm the prediction of the modeling.
Consequently, the equilibrium constants (KD) of scFv-IC16 to
various N-terminal Ab fragments were determined using SPR. For
comparison, we also performed the measurements with the
monoclonal parent antibody IC16 (Fig. 4 and 5, Table 3). The
monoclonal antibody was expected to exhibit more structural
stability caused by the constant domains. Additionally, an avidity
effect may influence the binding constants of IC16 to the different
Ab peptides. Measurements on both Ab(1-8) and Ab(8-15) were
used to confirm the localization of the linear binding epitope at the
N-terminal. No interaction of IC16 and scFv-IC16 with Ab(8-15)
was observed. For Ab(1-8) the injection curves showed a fast
association rate of IC16 and a very slow dissociation rate. This
result is reflected in the low KD of 51 nM (Table 3, bivalent fit).
Comparison of the binding curves of IC16 and scFv-IC16 revealed
that the association rates of scFv-IC16 and IC16 to Ab(1-8) were
comparable, whereas the dissociation rate of scFv-IC16 was one
order of magnitude higher than the corresponding IC16
dissociation rate. These results are reflected in the KD for scFv-
IC16 (KD of 0.55 mM, Table 3, Langmuir 1:1 binding model),
demonstrating a loss of affinity of the scFv in comparison to the
monoclonal antibody, which may be due to the lost avidity of the
scFv as compared to the monoclonal antibody.
A comparison of the affinities of both IC16 and scFv-IC16 for
N-terminally truncated Ab-peptides (Table 3) showed that the
highest affinities were observed for Ab(2-8). Deletion of A2 leading
to Ab(3-8) resulted in significant reduction of affinity for scFv-IC16
(Table 3). Truncation of the two N-terminal residues and
modification of E3 into pyroE3 led to an extensive loss of affinity
and no binding could be detected for scFv-IC16.
Influence of scFv-IC16 on Ab(1-42) Fibrilization
To characterize the influence of scFv-IC16 on Ab(1-42)
fibrilization, ThioflavinT (ThT) assays were carried out. ThT is
a benzothiazole dye, which exhibits a shift and increase in
quantum yield while binding to b-sheet rich fibrils [46]. During
the fibrilization process of Ab, an increase of ThT fluorescence
can be observed until a saturation level is reached. Whereas the
Figure 1. SDS-PAGE analysis of the purification of scFv-IC16 via
Ni-NTA and Ab1-16 GB1 NHS sepharose affinity chromatogra-
phy. 1 ml of the lysate and 15 ml of the purified fractions were applied
to 16% polyacrylamide gels [56]. Lane 1: cell lysate, lane 2: eluate after
affinity chromatography via Ni NTA–Agarose, lane 3: eluate after Ab1-
16-GB1-NHS-Sepharose affinity chromatography. Target protein is more
than 99% pure after final purification step.
doi:10.1371/journal.pone.0059820.g001
Figure 2. Sequence alignment of the VH (a) and VL (b) region of IC16 and PFA1. Residues belonging to the CDRs are marked in red.
Labeling was done according to the sequence of the heavy and light chain used for the scFv-IC16 construct, each starting with residue 1. Residues
that interact with Ab(1-8) are marked in bold and those residues that form hydrogen bonds or salt-bridges with Ab(1-8) are additionally underlined.
D1 of the IC16 light chain is marked in bold and blue, because it forms repulsive interactions with D1 of Ab.
doi:10.1371/journal.pone.0059820.g002
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Ab sample showed a strong increase in ThT fluorescence after
10 h, ThT assays with Ab and scFv-IC16 yielded a scFv-IC16
dose-dependent lower ThT signal (Fig. 6A), indicating a strong
influence of scFv-IC16 on Ab fibril formation. With the ratio of
1:1 for Ab(1-42) and scFv-IC16 the fibrilization of Ab(1-42) was
completely inhibited. At the ratios of 2:1 and 5:1, scFv-IC16
reduced the ThT fluorescence significantly. The sample that
contained only scFv-IC16 was used as a negative control and
did not show ThT fluorescence after 10 h.
ELISA Analysis of the Binding Activities of scFv-IC16 to Ab
Monomers, Oligomers and Fibrils
The monoclonal antibody IC16 was raised against Ab(1-16),
and binding activity of scFv-IC16 to N-terminal Ab fragments
was confirmed using SPR. Nonetheless, we intended to analyze
the binding activities of scFv-IC16 to different Ab conformers in
order to detect potential binding preferences. To perform
ELISA studies, Ab monomers, oligomers and fibrils were
prepared and equal molar amounts with respect to monomeric
Ab were immobilized in wells of a 96 well plate. The
commercially available monoclonal antibody 6E10 is known to
bind to all Ab conformers with similar affinities as it recognizes
human Ab(3-10) epitope, which is freely accessible in Ab
monomers as well as in oligomers and fibrils [47]. It is
frequently used as a standard in ELISA experiments [48,49,50]
and was used here as a control to compare the immobilized
amounts of Ab monomers, oligomers and fibrils. The different
Ab conformers were incubated with scFv-IC16. Subsequently,
bound scFv-IC16 was detected using an anti-His antibody that
was then detected by an HRP conjugated secondary antibody.
Fig. 6B depicts the relative quantification of the binding of scFv-
IC16 and 6E10 to different Ab conformers. The 6E10 control
demonstrated the presence of similar amounts of Ab monomers,
oligomers and fibrils with respect to monomeric Ab in the wells
of the microtiterplate. Furthermore, scFv-IC16 showed a prefer-
ential binding to Ab fibrils. The highest relative fluorescence
was detected for fibril binding; the relative fluorescence for
oligomer binding was weaker (p = 0.0014, N-bio oligomers to N-
bio fibrils). Signals for monomer binding were not detected if
Ab monomers were immobilized onto the streptavidin functio-
nalized surface of the well via an N-terminal biotin tag,
indicating interference of the N-terminal biotin tag with the
binding of scFv-IC16 to 100% N-terminally biotinylated
monomers. Ab monomers or Ab(1-10) fragments that were
immobilized via a C-terminal biotin tag were bound by scFv-
Figure 3. Interaction of monomeric Ab(1-8) with the antibodies PFA1 (left) and IC16 (right). Residues of Ab(1-8) are shown in stick
presentation and colored according to the atom type (residue D1 of Ab is not resolved in the PFA1 complex). For clarity, only D1, A2, R5, H6, and S8 of
Ab(1-8) are labeled. Key interacting residues of the antibodies are shown in ball-and-stick presentation and are labeled (chain identifier in
parenthesis). Polar attractive interactions formed by these residues are depicted in green line. A repulsive interaction between D1(L) and D1 of Ab(1-
8) is indicated by a blue double-headed arrow.
doi:10.1371/journal.pone.0059820.g003
Table 1. Comparison of the CDR sequences of the heavy
chains of different antibody fragments.
Name CDR1 CDR2 CDR3
scFv-IC16 GFSLSTSGMGV HIFWDDDKNYNPSLKSR RSPHLRGYDVDFDY
PFA1 GFSLSTSGMG IWWDDDR VRRAHTTVLGDWFAY
PFA2 GFSLRTSGMG IWWDDDK VRRAHNVVLGDWFAY
doi:10.1371/journal.pone.0059820.t001
Table 2. Comparison of the CDR sequences of the light
chains of antibody fragments.
Name CDR1 CDR2 CDR3
scFv-IC16 RSSQSLVHSNGNTYLH YKVSNRFS SQSTHVPLT
PFA1 QSIVHSNGNTY KVS FQGSHVPLTS
PFA2 QSIVHSNGNTY KVS FQGSHVPLTS
doi:10.1371/journal.pone.0059820.t002
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IC16 very similar to Ab oligomers in the ELISA experiment,
which can be shown by similar absorption values (p = 0.038, C-
bio monomers to N-bio oligomers; p = 0.19, C-bio Ab1-10 to
N-bio oligomers).
To confirm that scFv-IC16 also binds Ab that was naturally
secreted by 7PA2 cells, scFv-IC16 was coupled to NHS-
Sepharose and incubated with culture medium derived from
wildtype CHO cells or 7PA2 cells. 7PA2 cells secrete high
amounts of monomeric and lower oligomeric Ab species.
Previously it was demonstrated that serum stabilizes the
monomeric form of Ab, whereas oligomeric Ab accumulates
in the absence of serum [51]. As demonstrated in Fig. 6C, scFv-
IC16 efficiently precipitated monomeric Ab from 7PA2-CM
containing FCS as well as lower oligomeric Ab species from
CM of 7PA2 cells cultured without FCS. Thus, scFv-IC16
displays the same binding specificity as the monoclonal antibody
IC16 [36].
Ex vivo Staining of Plaques in Mouse Brain Slices
Brain cryosections derived from nine or 12 months old
transgenic (tg 2576) mice and the respective non-transgenic
control were stained using scFv-IC16. Additionally, anti-Ab
plaque stainings (using the 6E10 antibody) were performed on
adjacent sections as well as costainings with scv-IC16 and 1-11-
3 anti Ab(1-42) antibody. DAPI nuclei counterstainings were
performed on the same slides, respectively. Photomicrographs of
the stained slices and overlay images are shown in Figure 7.
scFv-IC16 could readily be used to detect plaques specifically in
AD transgenic mice with low background signals, demonstrating
potential applicability as a molecular probe. The staining
pattern of scFv-IC-16 was very similar to the staining pattern
of 6E10, which also binds to the N-terminal part of Ab and the
periphery of the plaques. The staining pattern of 1-11-3 is
slightly different as the core of the plaques is stained with higher
intensity.
Table 3. Rate constants and dissociation constants of the
interactions of scFv-IC16 and IC16 with N-terminal Ab
fragments.
Analyte Ligand kon (M
-1 s-1 ) koff (s
-1) KD (M)
scFv-IC16 Ab(1-8) 3.1060.026104 1.7260.00561022 5536461029
Ab(2-8) 6.8460.036104 7.6560.0361023 11260.661029
Ab(3-8) 8.3660.56103 43.960.361023 5.2560.361026
Ab(pE3-8) n.d.
Ab(8-15) n.d.
IC16 Ab(1-8) 3.560.026104 1.860.0261023 5160.561029
Ab(2-8) 4.8560.016104 1.5460.00661023 3260.161029
Ab(3-8) 4.1760.00661043.4360.00761023 8260.261029
Ab(pE3-8) 4.2160.00861046360.0561023 1.560.00161026
Ab(8-15) n.d.
Data were fitted globally. scFv-IC16 data were fitted according to the Langmuir
1:1 binding model, whereas IC16 data were fitted using a bivalent fit. The
association rate constants (kon), the dissociation rate constants (koff) and the
equilibrium dissociation constants (KD) are given below. Both, scFv-IC16 and
IC16, did not show any detectable binding towards Ab(8-15). However, they
showed binding to all N-terminal peptides, except scFv-IC16 did not bind to
Ab(pE3-8). The lowest KD value was observed for the interaction of scFv-IC16
and IC16 to Ab(2-8).
doi:10.1371/journal.pone.0059820.t003
Figure 4. Analysis of the binding affinity of scFv-IC16 to
immobilized Ab peptides. (A: Ab(1-8), B: Ab(2-8) and C: Ab(3-8))
using SPR. Depicted are the overlaid sensorgrams of different injection
concentrations of scFv-IC16 onto an Ab peptide coupled CM5 sensor
chip. Each injection was performed for 3 min at a flow rate of 20 ml/min.
Concentrations from 0 to 1000 nM were injected (see legend) in
consecutive order. Dissociation was observed 2 to 4 min following an
injection. Selected concentrations were injected twice as controls. The
experimental data were fitted using the Langmuir 1:1 binding model
(Ri = 0). [25uC; Running buffer: PBS, RmaxAb(1-8) = 67.5; RmaxAb(2-
8) = 553; RmaxAb(3-8) = 126].
doi:10.1371/journal.pone.0059820.g004
Antibody Fragment for Studies on Alzheimer’s
PLOS ONE | www.plosone.org 7 March 2013 | Volume 8 | Issue 3 | e59820
Discussion
Here we have characterized a novel scFv with respect to its
binding specificities to different Ab conformers and its influence on
Ab fibrilization. This scFv-IC16 was constructed from an IgG2a,
designated IC16, which was raised in mouse against the antigen
Ab(1-16) and binds to Ab(2-8) [36].
scFv-IC16 shares 87% sequence identity with of PFA1 and
PFA2 (see Figure 2), two Ab binding Fab fragments described by
Gardberg et al. [33]. Especially, the three CDRs of scFv-IC16 are
highly similar (see Tables 2 and 3), CDRs 1 of the heavy chain are
100% identical and CDRs 1 and CDRs 2 of the light chain are
91% and 100% identical, respectively. The striking WWDDD
motif within CDR2 of PFA1 and PFA2 that recognizes the Ab
binding motif EFRH (Ab(3-6)) [33,52] is almost completely
present in scFv-IC16, too: FWDDD. Because of the high sequence
homology between scFv-IC16 and PFA1, we assumed similar
interactions between scFv-IC16 and Ab as described for PFA1 and
Ab. Therefore, a homology modeling for the scFv-IC16-Ab
complex based on the X-ray structure of the Fab PFA1 and Ab(1-
8) was performed (Fig. 3). The model yielded similar binding
modes for scFv-IC16 to Ab(1-8) and PFA1 to Ab(1-8). However,
amino acid D1 of Ab was not resolved in the X-ray structure of the
Ab(1-8)/PFA1 complex. Our homology modeling placed it in
close spatial proximity with the amino acid D1 of the light chain.
This close spatial proximity may generate a repulsive force and
thus explains the increased affinity (KD,112 nM) of scFv-IC16 to
Ab(2-8) as compared to Ab(1-8) (Tab. 3). The model furthermore
offers an explanation why the KD rises to more than 5 mM when
the second amino acid A2 of Ab is truncated. A2 forms a hydrogen
bond with the backbone amide group of V99 of the heavy chain
and is therefore important for a tight binding. Deletion of residues
one and two and modification of Ab E3 into pyroE3, as found in
several truncated and more aggregation prone Ab species in the
diseased brain [53,54], showed a decrease in affinity and no
binding was observed for scFV-IC16.
In comparison, PFA 1 shows the strongest binding to Ab(1-40)
monomers (KD,39 nM). The binding to Ab(2-7) is in the same
order of magnitude (KD,60 nM). Similar to scFv-IC16, the
binding of PFA1 to Ab(pE3-8) is decreased, which is reflected in
the KD of ,3 mM [33,52]. pE3 lacks the E3 sidechain carboxyl
Figure 5. Analysis of the binding affinity of IC16 to immobilized Ab peptides. (A: Ab(1-8), B: Ab(2-8), C: Ab(3-8) and D: Ab(pE3-8)) using SPR.
Depicted are the overlaid sensorgrams of different injection concentrations of IC16 onto an Ab peptide coupled CM5 sensor chip. Each injection was
performed for 3 min at a flow rate of 20 ml/min. Concentrations from 0 to 1000 nM were injected (see legend) in consecutive order. Dissociation was
observed for 2 to 4 min. Selected concentrations were injected twice as additional controls. The experimental data were fitted using the bivalent
binding model (Ri = 0). [25uC; Running buffer: PBS; RmaxAb(1-8) = 169; RmaxAb(2-8) = 154; RmaxAb(3-8) = 121; RmaxAb(pE3-8) = 360].
doi:10.1371/journal.pone.0059820.g005
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group that forms two hydrogen bonds with S32(H) in the complex
crystal structure.
Due to the high sequence similarity between PFA1 and scFv-
IC16, similar interactions between scFv-IC16 and E3 of Ab are
also present in our modeled complex structure. Therefore, a loss of
the interactions described above may lead to a loss in affinity, so
that an interaction between scFv-IC16 and Ab(pE3-8) could not
be detected.
Altogether, the binding of scFv-IC16 to the Ab fragments is
weaker in comparison to PFA1. This may be due to small
differences in the binding pocket like the D108V replacement
(Fig. 3), but also to the fact that PFA1 is a Fab fragment, consisting
of the variable and one constant domain of the heavy chain and
the variable and the constant domain of the light chain. The two
constant domains may provide more stability for the binding
pocket of PFA1 compared with the binding pocket of scFv-IC16,
because its two variable domains are connected only via a peptide
linker lacking the stability of the two constant domains.
In a series of ELISA experiments, the specificity of scFv-IC16 to
different conformers of Ab, monomers, oligomers and fibrils, was
characterized. The non-conformation specific monoclonal anti-
body 6E10 was used to control the relative amount of bound Ab
conformer in the wells. 6E10 was previously characterized to bind
an Ab N-terminal epitope at residues 3 to 10. Similar ELISA
readouts for 6E10 and Ab monomers, oligomers and fibrils proved
that all three conformers were loaded in similar amounts into the
wells. The binding of scFv-IC16 to its epitope at residues 2–8 of
Ab monomers that were immobilized using an N-terminal biotin
tag was sterically hindered. As soon as the N-terminus was freely
accessible, e.g. in C-terminally biotinylated Ab monomers, scFv-
Figure 6. Inhibition of ThT positive Ab fibril formation in presence of different scFv-IC16 concentrations. (A). ScFv-IC16 was added in
concentrations of: 7.5, 3.75, 1.5 and 0 mM (positive control) to 7.5 mM Ab(1-42) samples. Data were recorded every 30 min during 22 hours of
incubation at room temperature. Depicted is the absolute fluorescence value after 10 h of incubation. Upon addition of ThT, fluorescence was
measured at 490 nm in relative units (mean +/2 standard deviations of results, each measurement was repeated five times). All values are corrected
by background fluorescence of ThT in PBS. ScFv-IC16 only control (7.5 mM) does not show any formation of ThT positive fibrils. A statistical significant
difference between the fluorescence values of Ab only and Ab-scFv-IC16 co incubations was calculated by student’s T-test, as indicated (**: p,0.01;
***: p,0.001). Analysis of an ELISA experiment to quantify the binding specificity of scFv-IC16 to different Ab1-42 conformers and Ab1-10 peptides
(B). 250 ng Ab1-42 (100% N-biotinylated monomers, 100% C-terminally biotinylated monomers, 10% N-biotinylated oligomers and fibrils) and 60 ng
Ab peptides 1–10 (100% C-terminally biotinylated Ab1-10, 100% N-terminally biotinylated Ab1-10) were immobilized on streptavidin coated 96 well
plates. 6E10 was used to monitor the immobilized amount of Ab conformers. Similar absorption values of 6E10 to the different Ab conformers except
for 100% N-terminally biotinylated monomers, indicate similar molar amounts of immobilized Ab regarding monomeric Ab for monomers, oligomers
and fibrils. Background absorption was subtracted from all samples. A highly significant difference in the relative fluorescence value between N-
biotinylated monomers and C-biotinylated monomers, as well as between C-bio Ab1-10 and N-bio Ab1-10 was calculated by Student’s t-test (***:
p,0.001). N-bio =N-terminally biotinylated; C-bio = C-terminally biotinylated. Western Blot of Ab monomers and low-n oligomers immunopreci-
pitated by scFv-IC16 from conditioned medium (CM) of CHO or 7PA2 cells (C). The latter were grown either in medium with or without FCS.
Monomeric Ab is stabilized by the presence of FCS, whereas low-n oligomeric Ab is eriched in CM-FCS. No Ab was precititated from the supernatants
of CHO cells. Monomeric Ab (CM 7Pa2+ FCS) and low-n oligomeric Ab (CM 7PA22 FCS) were equally bound by scFv-IC16. Detection antibody: 4G8.
doi:10.1371/journal.pone.0059820.g006
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IC16 bound Ab monomers with the same affinity as oligomers, as
judged by the ELISA results. A slightly higher ELISA signal was
detected for the binding to Ab fibrils. Given the fact that scFv-
IC16 binds to residues 2–8 of the N-terminus of Ab, specificity for
a special Ab conformer was not expected. In aggregated Ab
conformers, the N-terminus of Ab (Ab(1-9)) was described to be
disordered and accessible, whereas residues 10–22 and 30–40
adopt a b-strand conformation and are involved in fibrilization
[55]. As both, scFv-IC16 and 6E10, bind to the N-terminus of Ab,
a similar binding pattern after usage for ex-vivo plaque staining in
AD transgenic mice was expected. A significantly higher
concentration of scFv-IC16 was needed to perform proper plaque
staining in comparison to the monoclonal antibody 6E10. The
need of higher amounts of protein, however, can be balanced by
the fact that the scFv can be expressed in E. coli and produced in
reasonable amounts at low costs. An interesting option could also
be to enhance the affinity of scFv-IC16 to Ab by rational design or
directed evolution methods. In conclusion, scFv-IC16 has several
interesting features. It can be produced recombinantly, a fact that
also provides possibilities for sequence optimization. scFv-IC16
prevents the formation of ThT positive Ab(1-42) fibrils. It
recognizes all conformers of Ab as it binds to a linear N-terminal
epitope. Furthermore, it is suitable as a molecular probe, which
was demonstrated by ex vivo plaque staining in brain slices of AD
transgenic mice. Therefore, scFv-IC16 is interesting for therapeu-
tic, imaging and mechanistic studies.
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